
usd jun pm et
summari lead develop manufactur provid analyt instrument
complex servic life scienc drug discoveri industri applic
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
may stock trade
broad product line geograph coverag span
life scienc health care industri market
singl custom account total
revenu reduc risk view balanc
intens competit industri compani
oper howev cutting-edg technolog
requir remain relev present risk
technolog obsolesc fact
present signific integr execut risk
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
scientif inc lift
target price
five-year forward price-to-earnings averag
think premium valuat
histor averag justifi due declin
leverag earn mix significantli
shift past five year toward faster
annual adjust oper incom
interest expens period
averag march
significantli higher improv
leverag free cash
flow bolt acquisit share
repurchas addit back
fastest grow highest margin segment
life scienc contribut oper
incom compar on-going
shift toward profit higher
valuat view reflect higher return
capit faster earn growth /colin
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
board
corpor overview thermo fisher scientif lead provid life scienc tool
servic broad array end market includ pharma biotech compani academ
govern institut diagnost health care compani industri appli scienc
compani product servic includ laboratori analyt instrument biochem reagent
laboratori medic consum softwar servic research analysi discoveri
diagnosi think largest compani within marketplac broadest product offer
geograph coverag
life scienc solut sale provid reagent instrument consum use
biolog medic research discoveri product new drug vaccin well diagnosi
diseas life scienc solut includ four primari busi bioscienc genet scienc
clinic next-gener sequenc bioproduct
analyt instrument sale provid instrument consum softwar servic
use rang applic laboratori product line field segment
includ three primari busi chromatographi mass spectrometri chemic analysi
materi structur analysi
specialti diagnost sale offer wide rang diagnost test kit reagent cultur media
instrument associ product custom health care clinic pharmaceut industri
food safeti laboratori specialti diagnost product gener use increas speed
accuraci diagnos improv qualiti cost-effect patient care
laboratori product servic sale laboratori supplier offer virtual everyth
need oper lab combin self-manufactur sourc product segment
also includ comprehens offer outsourc servic use biopharmaceut firm drug
develop clinic trial logist commerci drug manufactur
corpor strategi think greatest strength lie industry-lead product breadth
across segment view creat one-stop shop effect allow research organ larg
small conveni order divers product need time cost-effect manner
one sourc exampl pharma custom start purchas mass spectromet
like eventu pitch sale rep save lab could gener switch
lab product supplier initi relationship may lead provid manufactur
servic compani downstream depart think breadth
product servic help gain market share concentr competitor way
continu expand product portfolio extens intern develop
extern growth via acquisit estim combin capital-expenditure roughli
line next three largest competitor combin also proven extrem effect
streamlin oper acquir firm execut billion worth acquisit sinc
end steadili increas adjust pre-tax incom margin period recent
notabl acquisit includ august acquisit patheon billion septemb
acquisit fei compani billion march acquisit affymetrix billion
februari acquisit billion
patheon ebita margin earn interest tax amort stand-alon
busi lower appear execut cost synergi overal ebita
margin maintain august acquisit also see strong
revenu growth opportun patheon clinic trial servic bioproduct technolog
expect improv margin scale grow
competit landscap life scienc tool servic marketplac highli fragment
competit think may competit advantag peer due purchas
power oper leverag broad product offer geograph coverag publicli trade competitor
includ water corp among privat held
firm vwr corpor primari competitor
financi trend sale increas billion billion repres
three-year compound annual growth rate compound-annual-growth-rate prolif acquir acquisit
aid sale growth adjust pre-tax incom per share rose
repres compound-annual-growth-rate estim ebita-to-interest coverag improv
last major acquisit patheon think repres
return conserv leverag level leav well-posit anoth major acquisit
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
lst sub-industri
next month think among
fastest-grow sub-industri within health
care sector driver earn growth
sub-industri next year
view strong growth public fund
health care research increas
spend biopharmaceut compani
demand growth emerg market
budget nation institut
nih grew rapidli last three year
materi increas fund academ
govern lab turn drive sale
growth mani lst compani suppli
lab nih fy sep budget
increas vs prior year follow
growth fy fy
respect mark major increas
averag increas fy fy
believ growth govern
fund boost sale lst
sub-industri grew rate greater
expect
anoth year robust sale growth
sub-industri although high
aid strong growth nih
addit publicly-fund health care
research expect larg increas privat
biopharmaceut spend also drive
sale growth lst sub-industri
estim total spend
 pharmaceut
 depart research tool softwar
well contract servic clinic drug
trial commerci think
biopharmaceut invest remain
strong year ahead treatment
innov cell gene therapi
develop provid anoth tailwind
sale growth lst sub-industri
beyond biopharmaceut industri
health care research type
prolifer around world particularli
china emerg market rapidli
grow middl class need access
advanc health care turn driven
strong intern sale growth
establish lst compani china
asia-pacif nation particular
estim sub-industri sale
asia-pacif region grew
howev tailwind may moder
somewhat note lst sale
growth region remain strong
estim year-over-year
despit slowdown nearli
like relat slower
econom growth china -china
nevertheless long term think china
major emerg market nation like
india need continu rapidli increas
health care expenditur parallel
grow middl class support
long-term sale growth lst
sub-industri see happen despit
neg impact import/export
tariff limit large-scal
supplier option state-of-the-art lst
product outsid compani
view notabl except
switzerland-bas roch
 life
vs drop
year-to-d april
lst rose gain
base index
five-year market price perform jun
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
pm et cfra maintain buy opinion share thermo fisher
scientif inc lift target price
ep estim maintain -- materi
five-year forward price-to-earnings averag think premium valuat
histor averag justifi due declin leverag earn mix
significantli shift past five year toward faster grow higher
margin busi ratio annual adjust oper incom interest
expens period averag march
significantli higher improv leverag free
cash flow bolt acquisit share repurchas
addit back fastest grow highest margin segment
life scienc contribut oper incom compar
on-going shift toward profit higher growth busi line
warrant higher valuat view reflect higher return capit
faster earn growth /colin scarola
scientif inc keep target
slightli above-p averag ep estim expect above-averag
growth initi ep estim ep vs beat
estim report strong quarter view top-lin
growth yoy fuel patheon acquisit last year
acceler organ growth segment especi impress
acceler organ sale growth life scienc yoy
believ indic grow market share rapidli grow
field especi import given life scienc largest segment
profit total also improv oper margin bp yoy
led success sg contain effort expect margin improv
next year strong track record streamlin
second year larg acquisit case patheon next year
et cfra maintain buy opinion share thermo fisher
scientif inc lift target
ep estim -- well-abov five-year forward price-to-earnings averag
think above-averag valuat justifi busi
shift significantli past five year faster grow higher
margin busi exampl fastest grow highest
margin segment life scienc contribut oper incom
gener shift help overal oper margin
improv basi point firm organ
revenu growth averag annual versu
expect organ growth remain elev strong demand
rapidli grow biopharmaceut field earn mix
increasingli shift toward profit high growth busi higher
price-to-earnings multipl justifi view reflect higher return capit
buy strong buy keep target
slightli below-p averag ep estim see rapid
organ acquisit growth recent year becom difficult
sustain due greatli increas scale follow patheon
acquisit august rais ep estim
opinion chang relat valuat share price increas
year-to-d push forward price-to-earnings multipl well beyond
averag respect expect growth remain strong particularli
china sale grow becom cautiou
valuat given larg scale like make meaning growth harder
achiev futur year remain support dual-strategi
invest heavili intern innov pursu acquisit track
record increas seri three major acquisit
past five year impress /colin scarola
et cfra maintain buy opinion share thermo fisher
scientif inc lift target
ep estim -- histor forward price-to-earnings averag
expect above-averag long-term growth maintain ep
estim ep vs beat consensu sale grew
yoy even stronger organ growth broad base four
segment achiev organ growth better life scienc
oper incom perform especi well yoy organ sale growth
saw robust demand biopharmaceut client addit despit
linger concern tariff china sale total grew
robust yoy indic strong competit posit countri
view adjust pre-tax incom grew yoy materi faster
sale pre-tax margin improv bp yoy think premium valuat
warrant due strong demand outlook improv oper
effici ampl dri powder /colin scarola
et cfra maintain buy opinion share thermo fisher
scientif inc keep target
ep estim long-term averag forward price-to-earnings
expect above-averag ep growth lower ep estim
keep ep vs beat forecast
report strong view top-lin growth yoy
driven solid growth across four oper segment life scienc
total revenu fastest grow
yoy respect driven continu robust demand
biopharmaceut custom china-bas buyer china sale growth
total remain strong yoy expect growth
market also improv pre-tax incom margin roughli bp yoy
expect improv margin trend continu
patheon acquisit integr major plant machineri
invest made harvest /colin scarola
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
